Year-over-year, this metric declined by 100.0%, from $216.00M to $0.00.
High acquisition spending indicates an aggressive growth strategy, while zero spending suggests a focus on organic growth or cash preservation.
The total capital deployed by the Pharmaceutical Diagnostics segment to acquire other businesses, technologies, or produ...
Comparable to 'cash paid for acquisitions' in segment-level cash flow disclosures for growth-oriented healthcare companies.
gehc_segment_pdx_acquisitions| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $216.00M | -$8.00M | $28.00M | $0.00 | $0.00 |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | — | — | — | -103.7% | +450.0% | -100.0% | — |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -100.0% |